ABSTRACT BACKGROUND Endocarditis has emerged as one of the most concerning adverse outcomes in patients with congenital
after TPVR (7) (8) (9) (10) . Endocarditis has also emerged as an important adverse outcome after transcatheter aortic valve replacement (13, 14) . To advance our insight into the incidence and outcomes of endocarditis after TPVR, and to evaluate potential risk factors for this time-related adverse event, we updated and expanded the analysis of data from the prospective multicenter valve trials.
METHODS
STUDY SUBJECTS AND PROTOCOLS. Similar to our prior report (4) Surveillance Study) in Europe and Canada. Details of these trials were summarized previously (4, (15) (16) (17) (18) (19) .
Patients were followed until study exit: the earliest of death, TPV explant, or completion of the prescribed follow-up duration (10 years IDE, 5 years for PAS and PMSS). The databases were locked for this study on November 18, 2016 (IDE and PAS), and September 29,
(PMSS).

DEFINITION AND ASCERTAINMENT OF ENDOCARDITIS
CASES. Patients who developed endocarditis were ascertained from the prospective study databases maintained by Medtronic, as summarized previously (4) . The diagnosis of endocarditis and involvement of the TPV were determined by the implanting investigator. Two adverse event codes for endocarditis were used: "endocarditis," which was intended to reflect TPV-related endocarditis, and "endocarditis other than TPV." "Endocarditis" was defined as "any infection involving the Melody TPV that meets the criteria for definite endocarditis according to the modified Duke Criteria," with the modified Duke criteria enumerated (20) . "Endocarditis other than TPV" was not specifically defined. Additional details related to definition and ascertainment of endocarditis cases are presented in the Online Appendix.
In addition to these definitions, objective evidence of TPV involvement was determined from data collected and incidence rates were presented with 95% confidence intervals (CIs). Incidence rates were compared between groups with incidence rate ratios, and 95%
CIs were calculated by assuming a Poisson model and considering the logarithm of the ratio. The SE was estimated in a logistical model, and a Ward 95% CI was calculated. Due to small numbers of implants within the trial at many centers, trial sites were combined into groups (i.e., by trial or number of implants) and incidence rate ratios were calculated. (31) 10 (22) 9 (26) 86 (33) Older adults $30 yrs 57 (18) 9 (20) 5 (14) 48 (18 Nonvalved synthetic tube 10 (3) 3 (7) 1 (3) 7 (3) Contegra 13 (4) 2 (4) 1 (3) 11 (4) Other stentless biological conduit
Implant duration of current conduit, yrs 9.7 (0. Values are median (minimum-maximum), n (%), or n/N (%), unless otherwise indicated. Hazard ratios reported are from univariate analysis. *Any endocarditis was analyzed in comparison to no endocarditis, and "TPV-related endocarditis" was compared with no TPV-related endocarditis. †Peak gradients refer to direct invasive measurements in the catheterization laboratory.
BPV ¼ bioprosthetic valve; RVOT ¼ right ventricular outflow tract; TPVR ¼ transcatheter pulmonary valve; TPVR ¼ transcatheter pulmonary valve replacement.
McElhinney et al.
Infectious organisms are summarized in Table 4 .
Staphylococcal species were most common (43%), followed by Viridans group streptococcal species (37%). Five patients had a known prior history of endocarditis (3 with different organisms), and 24 of 46 (52%) had some type of predisposing or mitigating condition, including dental procedures, cutaneous wounds or infections, and infection involving other intracardiac foreign material ( Table 4) . Three patients (all with Staph aureus) had septic pulmonary embolism documented by computed tomography (the total number of patients evaluated with computed tomography was not available).
The annualized incidence rate of endocarditis was There were considerable differences in endocarditis incidence rates among study centers. Table 5 , and additional details are provided in the Online Appendix.
TREATMENT AND OUTCOMES OF ENDOCARDITIS.
All patients with endocarditis were treated with antibiotics except for 2, who died before treatment could be initiated. Interventions in patients with TPV-and non-TPV-related endocarditis are summarized in Figure 2 , with further details in the Online Appendix.
Patients #12 years of age at implant who developed endocarditis were significantly more likely to undergo TPV explant and conduit replacement than patients who were older (62% vs. 21%; p ¼ 0.012).
A total of 5 patients died as a result of the infectious episode at 0, 4, 11, 37, and 63 days after diagnosis of endocarditis; 4 had a septic syndrome and 1 had pulmonary embolus. Two other patients with non-TPV-related endocarditis died 4 and 11 months later, unrelated to the endocarditis episode. A total of 4 of these 5 patients had staphylococcal infection (the other died soon after presentation and no organism was confirmed), and only 2 had evidence of TPV involvement. One of the 5 deaths was in a patient who was age #12 years at TPVR, and younger patients with endocarditis were no more likely to die than older patients (p ¼ 0.56). Values are n. These data are for first (not recurrent) post-TPVR endocarditis episodes. *Four of these patients had both stenosis and a stent fracture, and 3 had undergone redo TPVR and the second valve was without stenosis or stent fracture prior to the endocarditis diagnosis. †Five patients had "none" entered for this item, and 17 had "unknown" or no information entered. ‡Cochlear implant site excoriation, oral ulcers, oropharyngeal trauma from endoscopy, hand laceration, acne, pacemaker pocket incision breakdown and infection, recent tattoo, not specified (n ¼ 2). §Pneumonia (n ¼ 3), infected hemodialysis catheter, sinusitis and otitis, sinusitis and cellulitis, Streptococcal pharyngitis, upper respiratory infection, not specified. kAortic valve (n ¼ 2), rhythm device leads (n ¼ 2), ventricular septal defect patch (also aortic valve), tricuspid valve. Three of these patients also had TPV vegetations visualized and 1 had significant new RVOT obstruction.
PR ¼ pulmonary regurgitation; other abbreviations as in Table 2 . TPV-ENDOCARDITIS CLINICAL CLASSIFICATION SCHEME. It was possible to assign a numeric endocarditis severity grade to all patients, but classification of TPV involvement (alpha group) could not be determined in 4 due to incomplete data. Additional details are provided in Table 1 and the Online Appendix.
DISCUSSION RISK OF ENDOCARDITIS AFTER TPVR IN PATIENTS
WITH CHD. On the background of growing published data around transcatheter valve therapies and endocarditis (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) 21) , this large study of a prospectively followed cohort with over 1,600 years of post-TPVR evaluation contributes several important insights.
Notably, the risk of endocarditis after TPVR persisted through the 5-year follow-up period. This finding is not surprising, and was also reflected in the much smaller investigational study of TPVR using the Sapien valve (Edwards Lifesciences, Irvine, California), which documented cases at least 4 years after implant (21) . We also noted variability in endocarditis incidence rates among study centers, suggesting that random or center-related factors may be relevant determinants of risk, although lack of detailed data precluded further insight into these differences. A subset of patients presented with or developed severe RVOT obstruction sometimes with a clinically extreme presentation, a manifestation that was not specific to a particular organism or patient profile.
Multivariable analysis revealed higher post-TPVR RVOT gradient and younger age at implant to be risk factors for endocarditis. RVOT stenosis was previously associated with higher endocarditis risk (4,5), but an association with younger age has not been reported. Although a residual peak gradient of 15 mm Hg may seem modest, patients with obstructed RVOT conduits frequently manifest much higher gradients during exercise, even after TPVR with a good result, such that the gradient observed in the catheterization laboratory may not always reflect the true afterload burden (22) . Regardless, this finding supports aggressive pre-dilation, pre-stenting, and post-dilation to achieve maximum relief of RVOT obstruction at the time of TPVR, taking into account potential complications such as coronary compression and conduit rupture.
Other predisposing conditions or risk factors, including a history of endocarditis and temporally related dental work or cutaneous infections, were relatively common in prior reports (12), and such Values are n (%) of column total or median (minimum-maximum). *Event coded as TPV-related/evidence of TPV involvement reported on supplemental event form. †Data on TPV involvement not available for 1 patient in these groups. ‡New or progressive in severity compared to pre-endocarditis. §Total number/known to be with same organism.
HACEK ¼ Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella species; VGS ¼ viridans group Streptococcal species; other abbreviations as in Table 2 .
factors were reported in 52% of endocarditis cases in this series. However, due to the challenges in estimating their prevalence among the entire cohort, we could not assess the risk associated with such factors. 
Death without Explant or Endocarditis Alive without Any Events
The competing outcomes curve depicts cumulative incidences over time of endocarditis (blue line), explant without endocarditis (orange line), and death without explant or endocarditis (gray line), whereas the probability of being alive without any events is represented by the red line. TPVR ¼ transcatheter pulmonary valve replacement.
outcomes of endocarditis after TPVR, and potentially for RVOT/pulmonary valve endocarditis more broadly. Although additional data will be necessary to confirm the utility of this clinical scheme, it may help facilitate both appropriate and timely treatment as well as epidemiological observation and analysis that will lead to more effective prevention, identification, and treatment. While this system was not applied prospectively, we recommend its application in future reports, which will hopefully allow some standardization across the published data and facilitate deeper insights into the risk of and risk factors for endocarditis in this population. 
